Nothing Special   »   [go: up one dir, main page]

PT2370096T - Combinações antitumorais contendo anticorpos que reconhecem especificamente cd38 e citarabina - Google Patents

Combinações antitumorais contendo anticorpos que reconhecem especificamente cd38 e citarabina

Info

Publication number
PT2370096T
PT2370096T PT97753040T PT09775304T PT2370096T PT 2370096 T PT2370096 T PT 2370096T PT 97753040 T PT97753040 T PT 97753040T PT 09775304 T PT09775304 T PT 09775304T PT 2370096 T PT2370096 T PT 2370096T
Authority
PT
Portugal
Prior art keywords
antibodies recognizing
combinations containing
recognizing specifically
antitumor combinations
containing cytarabine
Prior art date
Application number
PT97753040T
Other languages
English (en)
Inventor
Lejeune Pascale
Vrignaud Patricia
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40627502&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2370096(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of PT2370096T publication Critical patent/PT2370096T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
PT97753040T 2008-11-28 2009-11-27 Combinações antitumorais contendo anticorpos que reconhecem especificamente cd38 e citarabina PT2370096T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08291118A EP2191842A1 (en) 2008-11-28 2008-11-28 Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine

Publications (1)

Publication Number Publication Date
PT2370096T true PT2370096T (pt) 2017-09-08

Family

ID=40627502

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97753040T PT2370096T (pt) 2008-11-28 2009-11-27 Combinações antitumorais contendo anticorpos que reconhecem especificamente cd38 e citarabina

Country Status (39)

Country Link
US (1) US20120093806A1 (pt)
EP (2) EP2191842A1 (pt)
JP (2) JP2012510463A (pt)
KR (1) KR101715958B1 (pt)
CN (2) CN102264386A (pt)
AR (1) AR073425A1 (pt)
AU (1) AU2009321251B2 (pt)
BR (1) BRPI0921858B1 (pt)
CA (1) CA2745005C (pt)
CL (1) CL2011001232A1 (pt)
CO (1) CO6440556A2 (pt)
CR (1) CR20110282A (pt)
DK (1) DK2370096T5 (pt)
EA (1) EA027070B1 (pt)
EC (1) ECSP11011071A (pt)
ES (1) ES2638926T3 (pt)
HN (1) HN2011001423A (pt)
HR (1) HRP20171301T1 (pt)
HU (1) HUE035910T2 (pt)
IL (2) IL213118A (pt)
LT (1) LT2370096T (pt)
MA (1) MA32899B1 (pt)
MX (1) MX344973B (pt)
NI (1) NI201100107A (pt)
NZ (1) NZ593085A (pt)
PA (1) PA8849901A1 (pt)
PE (1) PE20120205A1 (pt)
PL (1) PL2370096T3 (pt)
PT (1) PT2370096T (pt)
RS (1) RS56248B1 (pt)
SG (1) SG171821A1 (pt)
SI (1) SI2370096T1 (pt)
SM (1) SMT201700403T1 (pt)
TN (1) TN2011000242A1 (pt)
TW (1) TWI436770B (pt)
UA (1) UA104160C2 (pt)
UY (1) UY32266A (pt)
WO (1) WO2010061359A1 (pt)
ZA (1) ZA201104064B (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2191842A1 (en) * 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine
AU2011310696B2 (en) 2010-09-27 2016-06-02 Morphosys Ag Anti-CD38 antibody and lenalidomide or bortezomib for the treatment of multiple myeloma and NHL
UA112170C2 (uk) * 2010-12-10 2016-08-10 Санофі Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
BR112015006731A2 (pt) 2012-09-25 2017-07-04 Morphosys Ag combinações e usos das mesmas
CN112043826A (zh) * 2013-03-13 2020-12-08 赛诺菲 包含抗cd38抗体和卡非佐米的组合物
JP2016536314A (ja) * 2013-10-31 2016-11-24 サノフイ ヒトのがんを治療するための特異的抗ｃｄ３８抗体
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US20160067205A1 (en) 2014-09-09 2016-03-10 Janssen Biotech, Inc. Combination Therapies with Anti-CD38 Antibodies
CA2969717A1 (en) 2014-12-04 2016-06-09 Janssen Biotech, Inc. Anti-cd38 antibodies for treatment of acute myeloid leukemia
CA2986594A1 (en) 2015-05-20 2016-11-24 Tufts Medical Center, Inc. Anti-cd38 antibodies for treatment of light chain amyloidosis and other cd38-positive hematological malignancies
EA036789B1 (ru) 2015-06-22 2020-12-22 Янссен Байотек, Инк. Комбинированная терапия гемобластозов антителами к cd38 и ингибиторами сурвивина
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
US10746739B2 (en) * 2015-09-14 2020-08-18 Leukemia Therapeutics, LLC Identification of novel diagnostics and therapeutics by modulating RhoH
JP7027321B2 (ja) 2015-11-03 2022-03-01 ヤンセン バイオテツク，インコーポレーテツド 抗ｃｄ３８抗体の皮下製剤及びその使用
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
KR20200079293A (ko) 2017-10-31 2020-07-02 얀센 바이오테크 인코포레이티드 고위험 다발성 골수종을 치료하는 방법
MX2021011181A (es) 2019-03-15 2022-01-19 Morphosys Ag Anticuerpos anti-cd38 y sus composiciones farmacéuticas para el tratamiento de la enfermedad autoinmune mediada por autoanticuerpos.
US11655302B2 (en) 2019-06-10 2023-05-23 Sanofi Anti-CD38 antibodies and formulations
CN112876563B (zh) * 2019-11-29 2022-08-16 康诺亚生物医药科技（成都）有限公司 药物组合物及其制备方法和应用
BR112022010905A2 (pt) 2019-12-05 2022-09-06 Sanofi Aventis Us Llc Formulações de anticorpos anti-cd38 para administração subcutânea
JP2024503432A (ja) 2021-01-14 2024-01-25 モルフォシス・アーゲー 抗ｃｄ３８抗体及び抗ｃｄ３８抗体の使用
TW202302642A (zh) 2021-03-01 2023-01-16 德商莫菲西斯公司 用於治療抗體介導移植物排斥用途之抗ｃｄ３８抗體
CN113278075B (zh) * 2021-06-18 2021-12-14 芜湖森爱驰生物科技有限公司 一种炎症检测试剂盒
TW202321303A (zh) 2021-07-19 2023-06-01 德商莫菲西斯公司 抗pla2r自體抗體媒介膜性腎病變之治療

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
ATE356869T1 (de) 1990-01-12 2007-04-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
DE69233254T2 (de) 1991-06-14 2004-09-16 Genentech, Inc., South San Francisco Humanisierter Heregulin Antikörper
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
KR100654645B1 (ko) 1995-04-27 2007-04-04 아브게닉스, 인크. 면역화된 제노마우스 유래의 인간 항체
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
EP2314625B1 (en) 1996-12-03 2014-05-07 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
DK0970126T3 (da) 1997-04-14 2001-08-13 Micromet Ag Hidtil ukendt fremgangsmåde til fremstillingen af anti-humant antigen-receptorer og anvendelser deraf
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
CA2329940A1 (en) * 1998-06-05 1999-12-09 Mayo Foundation For Medical Education And Research Use of genetically engineered antibodies to cd38 to treat multiple myeloma
US20080057070A1 (en) * 2004-11-04 2008-03-06 Chiron Corporation Antagonist Anti-Cd40 Monoclonal Antibodies and Methods for Their Use
EP1866338B1 (en) * 2005-03-23 2016-09-21 Genmab A/S Antibodies against cd38 for treatment of multiple myeloma
HUE044136T2 (hu) * 2006-09-26 2019-09-30 Genmab As Anti-CD38 plusz kortikoszteroidok plusz nem-kortikoszteroid kemoterápiás szer daganatok kezelésére
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
WO2009094391A1 (en) * 2008-01-23 2009-07-30 Xencor, Inc. Optimized cd40 antibodies and methods of using the same
EP2191842A1 (en) * 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine

Also Published As

Publication number Publication date
JP6072854B2 (ja) 2017-02-01
CA2745005A1 (en) 2010-06-03
IL213118A0 (en) 2011-07-31
UY32266A (es) 2010-06-30
EA027070B1 (ru) 2017-06-30
BRPI0921858A2 (pt) 2018-10-09
BRPI0921858B1 (pt) 2022-11-16
ZA201104064B (en) 2012-09-26
US20120093806A1 (en) 2012-04-19
PA8849901A1 (es) 2010-07-27
CO6440556A2 (es) 2012-05-15
CR20110282A (es) 2011-09-20
MX344973B (es) 2017-01-12
IL213115A0 (en) 2011-07-31
LT2370096T (lt) 2017-09-25
TN2011000242A1 (en) 2012-12-17
NZ593085A (en) 2012-12-21
MA32899B1 (fr) 2011-12-01
HN2011001423A (es) 2014-01-13
CN107096022A (zh) 2017-08-29
HUE035910T2 (en) 2018-05-28
CN102264386A (zh) 2011-11-30
DK2370096T5 (en) 2017-09-18
MX2011005666A (es) 2011-09-30
UA104160C2 (uk) 2014-01-10
RS56248B1 (sr) 2017-11-30
AU2009321251A1 (en) 2010-06-03
AU2009321251B2 (en) 2016-06-09
DK2370096T3 (en) 2017-07-17
TWI436770B (zh) 2014-05-11
PE20120205A1 (es) 2012-03-03
SMT201700403T1 (it) 2017-11-15
IL213118A (en) 2017-08-31
NI201100107A (es) 2011-09-26
EP2370096B1 (en) 2017-05-31
WO2010061359A1 (en) 2010-06-03
TW201023863A (en) 2010-07-01
EA201100868A1 (ru) 2011-10-31
HRP20171301T1 (hr) 2017-10-20
JP2012510463A (ja) 2012-05-10
CL2011001232A1 (es) 2012-02-10
PL2370096T3 (pl) 2017-10-31
IL213115A (en) 2017-08-31
KR20110096551A (ko) 2011-08-30
JP2015205893A (ja) 2015-11-19
SG171821A1 (en) 2011-07-28
CA2745005C (en) 2020-08-11
ECSP11011071A (es) 2011-07-29
EP2370096A1 (en) 2011-10-05
SI2370096T1 (sl) 2017-10-30
KR101715958B1 (ko) 2017-03-14
EP2191842A1 (en) 2010-06-02
ES2638926T3 (es) 2017-10-24
AR073425A1 (es) 2010-11-03

Similar Documents

Publication Publication Date Title
ZA201104064B (en) Antitumor combinations containing antibodies recognizing specifically cd38 and cytarabine
HK1164165A1 (en) Antitumor combinations containing antibodies recognizing specifically cd38 and melphalan cd38
HK1164154A1 (en) Antitumor combinations containing antibodies recognizing specifically cd38 and cylophosphamide cd38
HK1164153A1 (en) Antitumor combinations containing antibodies recognizing specifically cd38 and vincristine cd38
HRP20181787T1 (hr) Antitumorske kombinacije koje sadržavaju protutijela koja specifično prepoznaju cd38 i bortezomib
GB2468261B (en) Enhanced note processing
IL209309A0 (en) Anti-fn14 antibodies and uses thereof
PL2949666T3 (pl) Ludzkie przeciwciała przeciwko alfa-synukleinie
IL216731A (en) And antibodies against p95 – her2 and their uses
GB0807018D0 (en) Antibodies and treatment
HK1146922A1 (en) Pencil
GB0803749D0 (en) Mouthpiece
HRP20190159T1 (hr) Antitijela humanog anti-alfa-sinukleina
GB0815918D0 (en) Pocket tops
TWM347415U (en) Band recognition structure
GB0818335D0 (en) Curl pearl
GB0801776D0 (en) Amusement rides